5 results about "Endocarditis" patented technology

The invention discloses application of alpha-hederin in preparation of a medicine for preventing or treating staphylococcus aureus infectious diseases, and belongs to the technical field of medicines. The staphylococcus aureus infectious disease is one of skin or soft tissue infection, pneumonia, osteoarthritis, mastitis, enteritis, endocarditis, urinary tract infection and enteritis. The medicine does not have an in-vitro direct sterilization function on sensitive and methicillin-resistant staphylococcus aureus, but can remarkably promote infected cells to remove thalli under a cell infection condition, so that the medicine plays a role in resisting sensitive and methicillin-resistant staphylococcus aureus infection by improving the anti-infection immune level of the cells.

The invention discloses a serum metabolism marker combination for diagnosing and classifying infectious endocarditis and a screening method thereof, and relates to the technical field of biological science. According to the method, a serum metabolism fingerprint spectrum is obtained through a matrix-assisted laser desorption / ionization mass spectrometry (MALDI MS) technology, and feature screening and model construction are carried out in combination with multiple machine learning models (including ridge regression, random forest, LASSO regression and the like). Through machine learning, five-fold cross validation is adopted to optimize model performance, and independent queue verification is utilized to evaluate generalization ability and overfitting risk. According to the technical scheme, rapid diagnosis and classification of IE can be achieved within 10 minutes, the pretreatment process is simple (an existing IE diagnosis method is complex in process and consumes 2-5 days), the requirements of clinical IE rapid screening and large-scale sample analysis can be met, and the method is suitable for industrial production. The detection flux is obviously improved; the cost is reduced.

A pharmaceutical composition according to one aspect comprises an oxazolidinone derivative or a pharmaceutically acceptable salt thereof, and thus can exhibit excellent prophylactic or therapeutic effects on diseases mediated by bacteria having resistance to penicillin-based compounds, and in particular, when used in combination with one or more antibiotics, can exhibit excellent effects such as an increase in overall healing rate, elimination of mediating bacteria, inhibition of an increase in severity, inhibition of occurrence of adverse events, an increase in safety, an increase in tolerability, and the like. Accordingly, the composition can be used as a therapeutic agent for penicillin-based compound-resistant bacteria-mediated diseases such as bacteremia, sepsis, endocarditis, and the like.

The present invention relates to peptides, fusion proteins and compositions for inducing an immune response against bacteria. The invention also relates to the treatment or prevention of infections by sepsis-inducing bacteria, and to the treatment and prevention of pathological conditions caused by such bacteria. Such pathological conditions include sepsis, pneumonia, meningitis, endocarditis, enterocolitis, urinary tract infection, soft tissue infection, gastrointestinal tract infection, bloodstream infection, encephalitis, premature delivery and dead delivery.

Alcohol-associated liver disease, particularly alcohol-associated hepatitis, constitutes a significant global health burden with high mortality rates. Imbalances in the gut microbiota are important for the progression of alcohol-associated liver disease, a condition classified as non-infectious. Disclosed herein are methods of treating or ameliorating a symptom of alcohol-associated hepatitis and methods of reducing or preventing mortality associated with alcohol-associated hepatitis. Also disclosed herein are methods of treating or ameliorating a symptom of sepsis, urinary tract infection, pneumonia, intra-abdominal infections, and / or endocarditis. Further disclosed are methods of determining responsiveness of a subject to treatment with the small molecule inhibitor C7, methods of identifying a subject for a clinical trial for treatment for alcohol-associated hepatitis and methods of screening for candidate compounds for treating alcohol-associated hepatitis.